Insider Trading Alert - NBY, WRES And ABTL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 3, 2014, 112 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $402.00 to $128,403,039.00.

Highlighted Stocks Traded by Insiders:

NovaBay Pharmaceuticals (NBY) - FREE Research Report

Wicks Tony D.S., who is Director at NovaBay Pharmaceuticals, sold 10,000 shares at $0.69 on Dec. 3, 2014. Following this transaction, the Director owned 213,680 shares meaning that the stake was reduced by 4.47% with the 10,000-share transaction.

The shares most recently traded at $0.72, up $0.03, or 4.17% since the insider transaction. Historical insider transactions for NovaBay Pharmaceuticals go as follows:

  • 4-Week # shares bought: 4,800
  • 12-Week # shares bought: 4,800
  • 12-Week # shares sold: 120,000
  • 24-Week # shares bought: 4,800
  • 24-Week # shares sold: 120,000

The average volume for NovaBay Pharmaceuticals has been 151,100 shares per day over the past 30 days. NovaBay Pharmaceuticals has a market cap of $34.6 million and is part of the health care sector and drugs industry. Shares are down 43.09% year-to-date as of the close of trading on Tuesday.

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. Currently, there are no analysts who rate NovaBay Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBY - FREE

TheStreet Quant Ratings rates NovaBay Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full NovaBay Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Warren Resources (WRES) - FREE Research Report

Waite Zachary C., who is Vice President Bus Development at Warren Resources, bought 200 shares at $2.01 on Dec. 3, 2014. Following this transaction, the Vice President Bus Development owned 200 shares meaning that the stake was boosted by 100% with the 200-share transaction.

The shares most recently traded at $1.80, down $0.21, or 11.67% since the insider transaction. Historical insider transactions for Warren Resources go as follows:

  • 4-Week # shares bought: 6,750
  • 4-Week # shares sold: 7,300
  • 12-Week # shares bought: 6,750
  • 12-Week # shares sold: 7,300
  • 24-Week # shares bought: 6,750
  • 24-Week # shares sold: 7,300

The average volume for Warren Resources has been 1.8 million shares per day over the past 30 days. Warren Resources has a market cap of $153.4 million and is part of the basic materials sector and energy industry. Shares are down 39.49% year-to-date as of the close of trading on Tuesday.

Warren Resources, Inc., an independent energy company, is engaged in the exploration, development, and production of onshore crude oil and gas reserves. The company holds interests in various properties that are located in California, Wyoming, New Mexico, and Texas. The company has a P/E ratio of 5.4. Currently, there is 1 analyst who rates Warren Resources a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WRES - FREE

TheStreet Quant Ratings rates Warren Resources as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Warren Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Autobytel (ABTL) - FREE Research Report

Fuller Glenn Evan, who is Evp, Clo, Secretary at Autobytel, bought 400 shares at $10.90 on Dec. 3, 2014. Following this transaction, the Evp, Clo, Secretary owned 6,400 shares meaning that the stake was boosted by 6.67% with the 400-share transaction.

The shares most recently traded at $10.84, down $0.06, or 0.55% since the insider transaction. Historical insider transactions for Autobytel go as follows:

  • 4-Week # shares bought: 13,544
  • 12-Week # shares bought: 13,544
  • 24-Week # shares bought: 13,544

The average volume for Autobytel has been 122,600 shares per day over the past 30 days. Autobytel has a market cap of $95.1 million and is part of the technology sector and internet industry. Shares are down 27.83% year-to-date as of the close of trading on Tuesday.

Autobytel Inc. operates as an automotive marketing services company in the United States. The company has a P/E ratio of 2.9. Currently, there are 2 analysts who rate Autobytel a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABTL - FREE

TheStreet Quant Ratings rates Autobytel as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Autobytel Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists